Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 17;61(5):911.
doi: 10.3390/medicina61050911.

The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review

Affiliations
Review

The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review

Rūta Mereškevičienė et al. Medicina (Kaunas). .

Abstract

Tuberculosis remains a significant public health challenge globally. The emergence of multidrug-resistant Mycobacterium tuberculosis strains presents one of the biggest hurdles in tuberculosis management. Both first- and second-line tuberculosis drugs are associated with common adverse reactions, which can lead to treatment interruptions and decreased adherence. In this article, we review the most commonly used drugs for the treatment of tuberculosis, focusing on the adverse reactions they may cause. We will examine the frequency and timeline of adverse drug reactions involving gastrointestinal, cardiac, neurological, nephrological, and cutaneous systems. Identifying patients at risk of developing those reactions is crucial for healthcare providers to implement monitoring strategies and manage complications effectively. In the review, we present the data about risk factors, management recommendations, and drug discontinuation rates as a result of side effects.

Keywords: adverse drug reactions; drug-resistant tuberculosis; drug-susceptible tuberculosis; first-line drugs; second-line drugs; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. World Health Organization (WHO) Global Tuberculosis Report. 2024. [(accessed on 1 February 2025)]. Available online: https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf....
    1. Prasad R., Singh A., Gupta N. Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis. Ann. Natl. Acad. Med. Sci. India. 2021;57:16–35. doi: 10.1055/s-0040-1722535. - DOI
    1. Dela A., Tank N.K., Singh A., Piparva K. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India. 2017;34:522. doi: 10.4103/0970-2113.217569. - DOI - PMC - PubMed
    1. Singh K.P., Carvalho A.C.C., Centis R., D’Ambrosio L., Migliori G.B., Mpagama S.G., Nguyen B.C., Aarnoutse R.E., Aleksa A., Van Altena R., et al. Clinical standards for the management of adverse effects during treatment for TB. Int. J. Tuberc. Lung Dis. 2023;27:506–519. doi: 10.5588/ijtld.23.0078. - DOI - PMC - PubMed
    1. Arbex M.A., Varella M.D.C.L., Siqueira H.R.D., Mello F.A.F.D. Drogas antituberculose: Interações medicamentosas, efeitos adversos e utilização em situações especiais—Parte 1: Fármacos de primeira linha. J. Bras. Pneumol. 2010;36:626–640. doi: 10.1590/S1806-37132010000500016. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources